Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Notice of Acceptance” issued by the State Drug Administration, and the company's application for a drug marketing license for Zhuoqibizumab injection (SHR-1819 injection) was accepted by the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.